三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

休市中 07-17 16:08:11

16.150

-1.760

-9.83%

最高18.120	最低15.610	成交量7,185万
今开18.110	昨收17.910	日振幅14.01%
总市值408.60亿	流通市值408.60亿	总股本25.30亿
成交额11.70亿	换手率2.84%	流通股本25.30亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":16.15,"timestamp":1784275691003,"preClose":17.91,"halted":0,"volume":71845827,"delay":0,"changeRate":-0.09826912339475162,"floatShares":2530000000,"shares":2530000000,"eps":3.43,"marketStatus":"休市中","change":-1.76,"latestTime":"07-17 16:08:11","open":18.11,"high":18.12,"low":15.61,"amount":1169782737,"amplitude":0.140145,"askPrice":16.15,"askSize":115000,"bidPrice":16.13,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":3.817726,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784511000000},"marketStatusCode":7,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":17.91,"dividendRate":0.016039,"openAndCloseTimeList":[[1784251800000,1784260800000],[1784264400000,1784275200000]],"volumeRatio":1.4860403745560473,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2652479358","title":"三生制药(01530)下挫9.77% 遭东方证券减持613.1万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652479358","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652479358?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:32","pubTimestamp":1784255524,"startTime":"0","endTime":"0","summary":"金吾财讯 | 三生制药(01530)盘中下挫9.77%，最新报16.16港元，成交额4.62亿港元。消息面上，港交所文件显示，东方证券已于7月10日减持三生制药613.1万股，每股作价17.8677港元，总金额约1.1亿港元。减持后东方证券持股数目约为1.77亿股，持股比例为6.97%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986120","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","BK1161","HK0000165453.HKD","BK0183","600958","BK1583","03958","BK0276","01530","BK1564","BK0028","BK0012","BK0188","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163099933","title":"异动解读｜三生制药盘中下跌5.64%，机构减持叠加生物科技板块回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1163099933","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163099933?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:08","pubTimestamp":1784254091,"startTime":"0","endTime":"0","summary":"7月17日，三生制药盘中下跌5.64%，报16.45港元/股，成交额3.43亿港元。消息面上，东方证券于7月10日减持三生制药613.1万股，每股作价约17.87港元，总金额约1.1亿港元，减持后持股比例降至6.97%。机构接连减持对市场情绪形成压制。三生制药是一家主要从事生物制药产品开发、生产及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物，同时从事CDMO业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651499914","title":"东方证券减持三生制药(01530.HK)613.1万股 每股作价约17.87港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651499914","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651499914?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:00","pubTimestamp":1784199627,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1147","BK1161","01530","BK1593","BK1564","HK0000165453.HKD","03958","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651291435","title":"创新药概念全线扬升 科伦博泰生物(06990)涨逾11% 机构指创新药企迎业绩兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2651291435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651291435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:07","pubTimestamp":1784084836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念盘中全线扬升，截至发稿，欧康维视生物-B 涨13.35%，科伦博泰生物涨11.20%，康方生物涨8.82%，信达生物涨8.72%，三生制药涨8.11%，康诺亚-B涨7.62%，药明合联涨7.52%，荣昌生物涨7.09%，乐普生物涨6.87%，亚盛医药涨6.26%。该机构持续看好国内创新药出海β向上可持续性，提示投资者关注2027年起众多前期已达成BD的分子将在海外开启商业化新周期所带来的投资机会。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","01477","LU0502904849.HKD","BK1191","IBBQ","LU0540923850.HKD","LU2476274308.USD","LU2097828557.USD","BK1593","01801","LU2097828714.EUR","02268","LU2097828631.EUR","LU2328871848.SGD","LU2097828805.USD","09995","LU0561508036.HKD","LU0348825331.USD","06855","LU0455707207.USD","LU2399975544.HKD","BK1587","KURE","LU0348827113.USD","LU2097828474.EUR","02157","06990","LU0348767384.USD","IE00B543WZ88.USD","MEDX","LU1961090484.USD","BK1161","BK1574","IE00BPRC5H50.USD","09926","02162","159992","LU0417516571.SGD","LU0634319403.HKD","LU0417516738.SGD","06978","LU0348784397.USD","LU1720050803.USD","LU2778985437.USD","SG9999014674.SGD","BK1589","BK1583","BK1141","LU0417516902.SGD","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183211465","title":"异动解读｜三生制药盘中上涨5.64%，报18.37港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183211465","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183211465?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:52","pubTimestamp":1784080334,"startTime":"0","endTime":"0","summary":"7月15日，三生制药盘中上涨5.64%，报18.37港元/股，成交额1.49亿港元。三生制药所在的生物科技行业中，个股普遍走强，其中科伦博泰生物涨9.49%，康方生物涨7.04%，信达生物涨6.5%，派格生物医药-B涨5.69%，百济神州涨1.99%。三生制药是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物，业务覆盖血小板减少症、慢性肾病贫血症、强直性脊柱炎等领域，同时从事CDMO业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651103132","title":"汇添富基金减持三生制药(01530.HK)613.1万股 每股作价约17.87港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651103132","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651103132?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:46","pubTimestamp":1784029619,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1583","HK0000165453.HKD","01530","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167855848","title":"异动解读｜三生制药盘中下跌5.49%，报17.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167855848","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167855848?lang=zh_cn&edition=full","pubTime":"2026-07-14 09:59","pubTimestamp":1783994390,"startTime":"0","endTime":"0","summary":"7月14日，三生制药盘中下跌5.49%，报17.06港元/股，成交额1.77亿港元。三生制药所在的生物科技行业中，个股普遍走弱，其中信达生物跌0.39%，百济神州跌0.75%，康方生物跌1.42%，科伦博泰生物跌2.42%，荣昌生物跌3.43%。三生制药是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物，业务覆盖血小板减少症、慢性肾病贫血症、强直性脊柱炎等领域，同时从事CDMO业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651289171","title":"【券商聚焦】中信证券：预计美妆行业在次季延续低速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2651289171","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651289171?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:55","pubTimestamp":1783990545,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，22026Q2，预计美妆行业在需求疲弱、流量成本走高、内容运营压力加大的背景下延续低速增长；结构性进一步分化，国际高端品牌销售反弹，本土大众、中端定位品牌承压；毛戈平、林清轩延续高增长，巨子生物、贝泰妮、敷尔佳销售底部回升。2026Q2，医美板块上游产品供给增加，竞争延续较高强度，四环医药受益于自主产品上市继续提升市场份额。估值已充分反映当前的经营压力且已严重低估，静候基本面改善和估值回升。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985765","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1511","KCE","BK1100","LU1064131003.USD","02138","BK1521","BK1583","LU0405327148.USD","LU2488822045.USD","BK1564","LU2289578879.USD","02196","BK1215","LU2495084118.USD","LU1997244956.HKD","LU1997245094.SGD","02373","BK0188","01696","BK1516","LU0405327494.USD","LU2148510915.USD","06030","BK0276","01530","LU1997245177.USD","00460","LU1794554557.SGD","600030","LU1720050803.USD","02367","LU1328615791.USD","LU1580142542.USD","BK1600","BK0028","BK1147","BK0196","BK1587","LU1064130708.USD","BK1515","LU1255011170.USD","LU1655091616.SGD","BK1585","BK1207","06699","HK0000165453.HKD","SG9999004311.SGD","BK0183","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136482764","title":"异动解读｜三生制药盘中上涨5.53%，报17.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136482764","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136482764?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:46","pubTimestamp":1783651599,"startTime":"0","endTime":"0","summary":"7月10日，三生制药盘中上涨5.53%，报17.96港元/股，成交额3.61亿港元。三生制药所在的生物科技行业中，个股普遍走强，其中派格生物医药-B涨39.42%，荣昌生物涨6.47%，康方生物涨4.97%，信达生物涨4.52%，百济神州涨2.58%。三生制药是一家集研发、生产和销售为一体的生物制药企业，主要产品包括特比澳、益比奥、益赛普等生物药物，业务覆盖血小板减少症、慢性肾病贫血症、强直性脊柱炎等领域，同时从事CDMO业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954218","title":"创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954218","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649954218?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:08","pubTimestamp":1783480087,"startTime":"0","endTime":"0","summary":"有研究指，创新药板块年内曾两轮短期反弹，本轮行情依托政策组合、高含金量海外交易、机构持续加仓三大不同支撑，但机构表示当前仅为估值修复行情，基本面全面反转仍需中期、三季度财报验证，后续走势重点跟踪企业盈利兑现与CGT正式政策落地进度。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU0456846285.SGD","LU1880383366.USD","IBBQ","LU1046422090.SGD","LU0348783233.USD","02359","06855","BK1191","06978","06990","SG9999002463.SGD","02269","01477","09926","LU0572944931.SGD","01952","LU0348784397.USD","LU2476274308.USD","KURE","LU0320764599.SGD","LU0819121731.USD","CZA","02268","LU3063872942.SGD","MEDX","REVS","LU0979878070.USD","00460","LU0052750758.USD","BK1141","BK1515","LU0196878994.USD","159992","01672","LU0516422440.USD","LU0588546209.SGD","LU0051755006.USD","01530","BK1521","06955","LU2242644610.SGD","BK1583","SG9999014674.SGD","LU0516423091.SGD","02186","LU0326950275.SGD","LU0140636845.USD","BK1600","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176418447","title":"异动解读｜三生制药盘中下跌5.24%，报18.45港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176418447","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176418447?lang=zh_cn&edition=full","pubTime":"2026-07-07 13:56","pubTimestamp":1783403760,"startTime":"0","endTime":"0","summary":"7月7日，三生制药盘中下跌5.24%，报18.45港元/股，成交额3.78亿港元。三生制药所在的生物科技行业中，个股普遍承压，其中荣昌生物跌6.49%，康方生物跌4.66%，信达生物跌3.59%，百济神州跌2.83%，科伦博泰生物跌2.48%。三生制药是一家集研发、生产和销售为一体的生物制药企业，主要产品包括特比澳、益比奥、益赛普等生物药物，业务覆盖血小板减少症、慢性肾病贫血症、强直性脊柱炎等领域，同时从事CDMO业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112918008","title":"异动解读｜三生制药盘中上涨6.67%，创新药支付改革催化叠加密集回购延续涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=1112918008","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112918008?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:49","pubTimestamp":1783043396,"startTime":"0","endTime":"0","summary":"7月3日，三生制药盘中上涨6.67%，报19.07港元，成交额2.33亿港元，延续前一交易日强势表现。同时，公司6月连续三日实施回购合计约852万股，耗资约1.35亿港元，董事长娄竞及汇添富基金此前亦分别增持，多方合力提振市场信心。生物科技板块同日延续强势，百济神州涨4.81%、荣昌生物涨5.06%、康方生物涨3.9%，板块联动效应显著。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124084942","title":"三生制药6月股份变动月报表：回购852.05万股并持作库存","url":"https://stock-news.laohu8.com/highlight/detail?id=1124084942","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124084942?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:32","pubTimestamp":1782984759,"startTime":"0","endTime":"0","summary":"三生制药于2026年7月2日发布了截至2026年6月30日的证券变动月报表。公告显示，公司6月期间通过三次集中交易累计回购8,520,500股普通股，并将其全部持作库存股份，回购价格区间为每股15.51631港元至15.99744港元，回购完成日期分别为2026年6月22日、25日及26日。报表显示，公司上月底已发行股份数目为2,538,084,412股，期末减少8,520,500股，至2,529,563,912股；库存股份数目由期初的0股增至8,520,500股，总已发行股份数保持2,538,084,412股不变。三生制药表示，目前已符合相关公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648575107","title":"港股直击 | 创新药概念股继续走高，创新药支付改革加速，药企有望持续步入业绩收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2648575107","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648575107?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:36","pubTimestamp":1782963369,"startTime":"0","endTime":"0","summary":"7月2日，创新药概念股继续走高，先声药业、三生制药涨超8%；信达生物涨超7%；康方生物涨近7%。消息面上，国家医保局公布2026年医保目录初审结果，共有557个药品通过医保目录初审，54个药品通过商保创新药目录初审，意味着“医保+商保”双目录谈判进入实质推进阶段。与此同时，预申报机制、8年价格保护等新机制同步落地，进一步完善创新药支付体系，为创新药商业化提供更加稳定的政策预期。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462173.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348825331.USD","LU0417516571.SGD","LU0417516902.SGD","LU2097828631.EUR","LU1961090484.USD","BK1161","VXUS","BK4588","IE00B5MMRT66.SGD","LU2097828557.USD","01801","LU2097828805.USD","BK4585","01530","LU1794554557.SGD","LU0561508036.HKD","BK1574","LU0348766576.USD","LU0348767384.USD","LU0348784397.USD","LU2097828474.EUR","IE00BPRC5H50.USD","BK1589","159992","LU0455707207.USD","LU2328871848.SGD","BK1583","LU2476274720.SGD","LU1969619763.USD","LU0502904849.HKD","LU2778985437.USD","06978","LU2488822045.USD","HK0000165453.HKD","09926","LU0417516738.SGD","LU0348735423.USD","LU2399975544.HKD","LU2097828714.EUR","02096","BK1593","LU1720050803.USD","LU0540923850.HKD","BK1191","LU2242644610.SGD","LU0348783233.USD","LU0348827113.USD","IE00B543WZ88.USD","LU0634319403.HKD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112047017","title":"异动解读｜三生制药盘中上涨11.78%，密集回购叠加板块共振推动股价放量走高","url":"https://stock-news.laohu8.com/highlight/detail?id=1112047017","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112047017?lang=zh_cn&edition=full","pubTime":"2026-07-02 09:59","pubTimestamp":1782957556,"startTime":"0","endTime":"0","summary":"7月2日，三生制药盘中上涨11.78%，报18.38港元，成交额3.69亿港元。消息面上，公司近期密集回购叠加管理层及机构增持形成合力，6月22日、25日、26日连续三日实施回购，合计回购约852万股，耗资约1.35亿港元；董事长娄竞于6月8日增持51.6万股，汇添富基金于6月10日增持63.65万股。同日生物科技板块整体走强，科伦博泰生物涨7.75%、信达生物涨6.47%、康方生物涨6.3%，板块联动效应显著。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","LU0634319403.HKD","02157","LU0348827113.USD","LU2476274720.SGD","IE00B543WZ88.USD","01093","HK0000165453.HKD","LU0348784397.USD","LU1961090484.USD","LU0067412154.USD","LU2476274308.USD","09926","LU0140636845.USD","LU0072913022.USD","LU1008478684.HKD","BK1574","LU0348825331.USD","LU0315179316.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU1328277881.USD","LU1969619763.USD","02162","LU0417516571.SGD","IE00BZ08YS42.EUR","LU0348766576.USD","LU0326950275.SGD","159992","LU1226287529.USD","06978","02637","LU1226288253.USD","LU1951186391.HKD","09969","LU1960683339.HKD","LU1993786604.SGD","02228","LU1226287792.SGD","LU0348783233.USD","LU0417516902.SGD","BK1583","LU0880133367.SGD","09995","LU0540923850.HKD","LU0348767384.USD","01530","06855","LU1720050803.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106268548","title":"异动解读｜三生制药盘中上涨5.66%，连续大手笔回购提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1106268548","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106268548?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:11","pubTimestamp":1782699118,"startTime":"0","endTime":"0","summary":"6月29日，三生制药盘中上涨5.66%，报16.9港元，成交额2.06亿港元。消息面上，公司近期密集回购股份，6月22日、25日、26日连续三日实施回购，合计回购约852万股，累计耗资约1.35亿港元，回购价格区间为15.40至16.01港元。此外，董事长娄竞于6月8日增持51.6万股，汇添富基金于6月10日增持63.65万股，管理层及机构持续加仓传递积极信号。同日生物科技板块整体走强，康方生物涨8.1%、信达生物涨5.19%、百济神州涨3.13%，板块联动效应明显。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119901644","title":"三生制药6月26日回购4,046,000股，耗资约6,437.68万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119901644","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119901644?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:12","pubTimestamp":1782472378,"startTime":"0","endTime":"0","summary":"2026年6月26日，三生制药发布翌日披露报表，宣布于当日通过香港联合交易所场内回购公司股份4,046,000股，占回购前公司已发行股份约0.16%。每股回购价介乎15.80港元至16.00港元，合计耗资约6,437.68万港元。公告显示，在本次回购后的30天内，即截至2026年7月26日，三生制药不得发行新股或出售、转让任何库藏股份，除非获得香港联交所批准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药6月26日回购4,046,000股，耗资约6,437.68万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646780886","title":"三生制药(01530.HK)6月25日斥资约5537.52万港元回购346.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646780886","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646780886?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:29","pubTimestamp":1782390552,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","HK0000165453.HKD","BK1593","01530","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646871804","title":"三生制药：8月4日将派发股息0.25港元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646871804","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646871804?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:08","pubTimestamp":1782382080,"startTime":"0","endTime":"0","summary":"南财智讯6月25日电，三生制药（01530.HK）公告，公司于2026年6月25日召开的股东周年大会上，审议通过了截至2025年12月31日止年度末期股息分配方案，拟向登记在册股东派发末期股息每股普通股25港仙（即0.25港元）。股权登记日为2026年7月27日，预计派息日为2026年8月4日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606253783197234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1161","BK4588","HK0000165453.HKD","BK1583","EWH","BK4585","VIG","01530"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.1063},{"period":"1month","weight":0.0056},{"period":"3month","weight":-0.3606},{"period":"6month","weight":-0.3901},{"period":"1year","weight":-0.468},{"period":"ytd","weight":-0.3321}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0103},{"period":"3month","weight":-0.0611},{"period":"6month","weight":-0.085},{"period":"1year","weight":0.0026},{"period":"ytd","weight":-0.0417}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.00666},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00178},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113214},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.080954},{"month":6,"riseRate":0.727273,"avgChangeRate":0.025344},{"month":7,"riseRate":0.083333,"avgChangeRate":-0.038717},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.014022},{"month":9,"riseRate":0.636364,"avgChangeRate":0.027455},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018307},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059913},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045323}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}